The following consensus is up to date for Dr. Martens as at 14th March 2025
| FY24A Year ending March 2024 (Reported) |
FY25E Year ending March 2025 |
FY26E Year ending March 2026 |
FY27E Year ending March 2027 |
|
|---|---|---|---|---|
| Revenue (£m) | £877.1 | £796.5 | £852.4 | £902.3 |
| Revenue CC (£m) | £807.1 | £843.7 | £885.3 | |
| EBIT (£m | £122.2 | £61.4 | £95.4 | £110.9 |
| Adjusted PBT (£m) | £97.2 | £32.0* | £67.5* | £84.7 |
| EPS (p) | 7.0 | 1.4 | 5.1 | 6.4 |
| DPS (p) | 2.55 | 2.54 | 2.07 | 2.32 |
The above consensus is the mean average of forecasts gathered from 8 out of 9 covering sell-side analysts (FY25E) and 9 out of 9 covering sell-side analysts (FY26E and FY27E)
*Please note, the calculation for the average adjusted PBT for FY25E and FY26E excludes one outlier
Legal disclaimer
These financial forecasts are not prepared nor endorsed by Dr. Martens in any way. Dr. Martens has no current or pending duty to verify any individual estimates and assumes no responsibility to update, revise or otherwise comment on any of the information contained in these forecasts. It should be noted that financial forecasts are, by definition, forward looking, and are therefore subject to various risks and uncertainties which are subject to change at any time.
